ArticleFrontiers in pharmacology2022
Tetracycline-grafted mPEG-PLGA micelles for bone-targeting and osteoporotic improvement.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Surface-Engineered Phytochemical Nanomedicines for Postmenopausal Osteoporosis: Skeletal Targeting, Imaging-Supported Evaluation, and Therapeutic Performance.Pharmaceutics · 2026Review
- Nanodrug delivery systems enhance traditional Chinese medicine treatment of osteoporosis.Discover nano · 2026Review
- Translational Nanomedicine for Osteoporosis: Bridging Bone Signaling Networks and Targeted Delivery Systems.International journal of nanomedicine · 2026Review
- From Conventional to Next-Generation Strategies: Recent Advances in Polymeric Micelle Preparation for Drug Delivery.Pharmaceutics · 2025Review
- Formulation and Characterization of Bone-Targeting Vancomycin-Loaded Liposomes.Pharmaceutics · 2025Article
- Leveraging Nanoscience and Strategic Delivery for the Expedition of Osteoporosis.AAPS PharmSciTech · 2025Review
- Natural bioactive products in the regulation of bone metabolism and regeneration.Frontiers in pharmacology · 2025Review
- Macrophage polarization in disease therapy: insights from astragaloside IV and cycloastragenol.Frontiers in pharmacology · 2025Review
- Potential Targeting Mechanisms for Bone-Directed Therapies.International journal of molecular sciences · 2024Review
- Harnessing the Potential of PLGA Nanoparticles for Enhanced Bone Regeneration.Pharmaceutics · 2024Review
- Integrating osteoimmunology and nanoparticle-based drug delivery systems for enhanced fracture healing.Nanomedicine : nanotechnology, biology, and medicine · 2024Review
- Design of Nanodrug Delivery Systems for Tumor Bone Metastasis.Current pharmaceutical design · 2024Review
- Bone Targeting Nanoparticles for the Treatment of Osteoporosis.International journal of nanomedicine · 2024Review
- An update on the advances in the field of nanostructured drug delivery systems for a variety of orthopedic applications.Drug delivery · 2023Article
- Citric acid-modified pH-sensitive bone-targeted delivery of estrogen for the treatment of postmenopausal osteoporosis.Materials today. Bio · 2023Article
- mRNA nanodelivery systems: targeting strategies and administration routes.Biomaterials research · 2023Review
- Targeting strategies for bone diseases: signaling pathways and clinical studies.Signal transduction and targeted therapy · 2023Review
- Development of tetracycline-modified nanoparticles for bone-targeted delivery of anti-tubercular drug.Frontiers in bioengineering and biotechnology · 2023Article
- Recent developments in nanomaterials for upgrading treatment of orthopedics diseases.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.